AstraZeneca is no longer seeking FDA approval for its Covid-19 prevention antibody known as sipavibart, a company spokesperson confirmed to Endpoints News.
The monoclonal antibody was meant to be a successor to AstraZeneca’s former blockbuster ...
↧